The challenge of follow-on biologics for treatment of multiple sclerosis

Neurology

Volumn 73, Issue 7, 2009, Pages 552-559

  Reingold, S C ^a   Steiner, J P ^b   Polman, C H ^c   Cohen, J A ^d   Freedman, M S ^e   Kappos, L ^f   Thompson, A J ^g   Wolinsky, J S ^h  

^a Scientific and Clinical Review Associates LLC   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF OTTAWA   (Canada)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; BIFERONEX; BLASTOFERON; EXTAVIA; GENERIC DRUG; GLATIRAMER; HUMAN GROWTH HORMONE; MECASERMIN RINFABATE; NATALIZUMAB; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; UNCLASSIFIED DRUG;

BIOEQUIVALENCE; CONSUMER; DRUG APPROVAL; DRUG EFFICACY; DRUG MANUFACTURE; DRUG MARKETING; DRUG SAFETY; FOLLOW UP; HUMAN; IMMUNOGENICITY; INJECTION SITE REACTION; MULTIPLE SCLEROSIS; PATENT; PRIORITY JOURNAL; PURE RED CELL ANEMIA; REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 69449098530     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181b2a6ce     Document Type: Article

References (49)

1. Woodcock J. Testimony before the US House of Representatives Committee on Oversight and Government Reform on "Follow-on Protein Products," May 2007 [online]. Available at: http://www.fda.gov/ola/2007/protein32607.html. Accessed March 27, 2009.
2. Ehrlich E, Wright EL. Biogenerics, May 2007 [online]. Available at: http://www.cagw.org/site/DocServer/Biogenerics-FINAL.pdf?docID=2221. Accessed March 27, 2009.
3. Food and Drug Administration, Center for Biologics. Frequently Asked Questions, 2008 [online]. Available at: http://www.fda.gov/cber/faq.htm#3. Accessed March 27, 2009.
4. European Medicines Agency. Guideline on similar biological medicinal products, 2005 [online]. Available at: http://www.emea.europa.eu/pdfs/human/ biosimilar/043704en. Accessed March 27, 2009.
5. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substances: quality issues, 2006 [online]. Available at: http://www.emea.europa.eu/pdfs/human/ biosimilar/4934805en. Accessed March 27, 2009.
6. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived protein as active substances: non-clinical and clinical issues, 2006 [online]. Available at: http://www.emea.europa.eu/pdfs/human/biosimilar/4283205en. Accessed March 27, 2009.
7. European Medicines Agency. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins, 2007 [online]. Available at: http://www.emea.europa.eu/pdfs/human/biosimlar/1432706en. Accessed March 27, 2009.
8. Schellekens H. Biosimilar therapeutics: what do we need to consider? NDT Plus 2009;2(suppl 1):i27-i36.
9. European Medicines Agency. Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substances: non-clinical and clinical issues. Guidance on similar medicinal products containing recombinant erythropoietins, 2006 [online]. Available at: http://www.emea.europa.eu/pdfs/human/biosimilar/9452605en. Accessed March 27, 2009.
10. European Medicines Agency. Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substances: non-clinical and clinical issues. Guidance on similar medicinal products containing somatotropin, 2006 [online]. Available at: http://www.emea.europa.eu/pdfs/human/biosimilar/9452805en. Accessed March 27, 2009.
11. European Medicines Agency. Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substances: non-clinical and clinical issues. Guidance on similar medicinal products containing recombinant human soluble insulin, 2006 [online]. Available at: http://www.emea.europa.eu/pdfs/human/biosimilar/3277505en. Accessed March 27, 2009.
12. European Medicines Agency. Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substances: non-clinical and clinical issues. Guidance on similar medicinal products containing recombinant granulocyte-colony stimulating factor (G-CSF), 2006 [online]. Available at: http://www.emea.europa.eu/pdfs/human/biosimilar/ 3132905en. Accessed March 27, 2009.
13. Swiss Agency for Therapeutic Products. Anleitung für die Zulassung änlicher biologischer Arzneimittel (Biosimilars)/Instructions relatives à l'autorisation de medicaments biosimilaires. Swissmedic Journal, February 2008:75-82 [online]. Available at: http://www.swissmedic.ch/org/00064/ 00065/index.html?lang=en. Accessed March 27, 2009.
14. Health Canada. Draft guidance for sponsors: Information and submission requirements for subsequent entry biologics (SEBs), 2008 [online]. Available at: http://www.hc-sc.gc.ca/dhp-mps/brgtherap/activit/consultation/seb-pbu/2008-2- eng.php. Accessed March 27, 2009.
15. Miller S, Houts J. Potential Savings of Biogenerics in the United States. Express Scripts, February 2007 [online]. Available at: http://www.express- scripts.com/industryresearch/outcomes/onlinepublications/study/ potentialSavingsBiogenericsUS.pdf. Accessed March 27, 2009.
16. Charles D. Approval of generic biologics: why we can't afford a dangerous shortcut. Neurol Today 2007;7:4-5 [online]. Available at: http://www. neurotodayonline.com/pt/re/neurotoday/pdfhandler.00132985-200707030-00003. pdf;jsessionid=JvqWysJN9lm9z0pkY2Sz3hVMFlNLcZnN2DMxp4shS9LjpnQqpfpK!- 317259742!181195629!8091!-1. Accessed March 27, 2009.
17. Gerrard T. Testimony before the Committee on Oversight and Government Reform: safe and affordable biotech drugs-the need for a generic pathway, March 26, 2007 [online]. Available at: http://oversight.house.gov/documents/ 20071102161216.pdf. Accessed March 27, 2007.
18. Schwieterman W. Testimony before the Committee on Oversight and government Reform: safe and affordable biotech drugs-the need for a generic pathway, March 26, 2007 [online]. Available at: http://oversight.house.gov/ documents/20071102161216.pdf. Accessed March 27, 2009.
19. Federal Food, Drug, and Cosmetic Act [online]. Available at: http://www.fda.gov/opacom/laws/fdcact/fdcact5a.htm#sec505. Accessed March 27, 2009.
20. Food and Drug Administration. Orange Book [online]. Available at: http://www.fda.gov/cder/ob/docs/preface/eclink.htm. Accessed March 27, 2009.
21. Berg MJ, Gross RA, Tomaszewski MS, Zingaro WM, Haskins LS. Generic substitution in the treatment of epilepsy. Neurology 2008;71:525-530.
22. Roger SD, Mikhail A. Biosimilars: opportunity or cause for concern? J Pharm Pharmaceut Sci 2007;10:405-410.
23. Stryer L. Biochemistry. 2nd ed. San Francisco: W.H. Freeman; 1981:789-813.
24. Liao JK, Laufs U. Pleiotropic effects of statins. Ann Rev Pharmacol Toxicol 2005;45:89-118.
25. US Food and Drug Administration. Tysabri package insert [online]. Available at: http://www.fda.gov/cder/foi/label/2006/125104s015lbl.pdf. Accessed March 27, 2009.
26. Stryer L. Biochemistry. 2nd ed. San Francisco: W.H. Freeman; 1981:11-38.
27. Petsko GA, Ringe D. Protein Structure and Function. London: New Science Press; 2004:11-46.
28. Walsh CT, Garneau-Tsodikova S, Gatto GJ Jr. Protein post-translational modifications: the chemistry of proteome diversifications. Angew Chem Int Ed Engl 2005;44:7342-7372. (Pubitemid 41689988)
29. Cohen BA, Oger J, Gagnon A, Giovannoni G. The implications of immunogenicity for protein-based multiple sclerosis therapies. J Neurol Sci 2008;275:7-17.
30. Frost H. Antibody-mediated side effects of recombinant proteins. Toxicology 2005;209:155-160. (Pubitemid 40568643)
31. Weinstock-Guttman B, Ramanathan M, Zivadinov R. Interferon beta treatment for relapsing multiple sclerosis. Expert Opin Biol Ther 2008;8:1435-1447.
32. Sominanda A, Rot U, Suoniemi M, Deisenhammer F, Hillert J, Fogdell-Hahn A. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity. Mult Scler 2007;13:208-214. (Pubitemid 46592773)
33. Farrell RA, Giovannoni G. Measuring and management of anti-interferon antibodies in subjects with multiple sclerosis. Mult Scler 2007;13:567-577. (Pubitemid 46939521)
34. Goodin DS, Frohman EM, Hurwitz B, et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007;68:977-984. (Pubitemid 46569129)
35. Sørensen PS, Deisenhammer F, Duda P, et al. Guidelines on the use of anti-IFN-beta antibody measures in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005;12:817-827. (Pubitemid 41597593)
36. Woodcock J, Griffin J, Behrman R, et al. The FDA's assessment of follow-on protein products: a historical perspective. Nat Drug Discovery 2007;6:437-442. (Pubitemid 47078655)
37. Mossinghoff GJ. Overview of the Hatch-Waxman Act and its impact on the drug development process. Food Drug Law J 1999;54:187-194.
38. Wadman M. Bills target biosimilars drugs. Nature 2009;458:394-395.
39. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol 1996;39:6-16. (Pubitemid 26052212)
40. McFarland HF, Reingold SC. The future of MS therapies: redesigning MS clinical trials in a new therapeutic era. Mult Scler 2005;11:669-676.
41. European Medicines Agency. Guideline on the choice of the non-inferiority margin, 2005 [online]. Available at: http://www.emea.europa.eu/pdfs/human/ewp/ 215899en. Accessed March 27, 2009.
42. European Medicines Agency. Guideline on comparability of biotechnology-derived medicinal products after a change in the manufacturing process: non-clinical and clinical issues, 2007 [online]. Available at: http://www.emea.europa.eu/pdfs/human/biosimlar/10169506enfin.pdf. Accessed March 27, 2009.
43. European Medicines Agency. Note for guidance on biotechnological/ biological products subject to changes in their manufacturing process (CPMP/ICH/5721/03), 2005 [online]. Available at: http://www.emea.europa.eu/pdfs/ human/ich/572103en.pdf. Accessed March 27 2009.
44. European Medicines Agency. Rebif. Procedural steps taken and scientific information after the authorization. Changes made after 01/03/2004, 2009 [online]. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Rebif/H- 136-en8b.pdf. Accessed March 27, 2009.
45. European Medicines Agency. Committee for medicinal products for human use. Summary of positive opinion for Extavia, 2008 [online]. Available at: http://www.emea.europa.eu/pdfs/human/opinion/Extavia-13863908en.pdf. Accessed March 27, 2009.
46. Mack G. FDA balks at Myozyme scale-up. Nat Biotechnol 2008;26:592.
47. European Medicines Agency. Questions and answers on recommendations for the refusal of the marketing authorization for BIFERONEX, 2009 [online]. Available at: http://www.emea.europa.eu/pdfs/human/opinion/BiferonexQ&A- 9112009en.pdf. Accessed March 27, 2009.
48. Bennett CL, Luminari S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004;351:403-408. (Pubitemid 39288166)
49. Kaufmann M, Papouchado M, Gonzalez E, et al. Early post-marketing pharmacovigilance of BLASTOFERON®: an interferon beta 1a biosimilar. Drug Saf 2008;31:885.